EATG » Scientific research

Scientific research

Integral Molecular’s protein engineering technology facilitates HIV vaccine development

PHILADELPHIA, March 13, 2018 - Integral Molecular, the industry leader in engineering membrane proteins, has extended its protein engineering capabilities to stabilize viral proteins and produce more effective candidate vaccines…

NIH experts call for transformative research approach to end TB

A more intensive biomedical research approach is necessary to control and ultimately eliminate tuberculosis (TB), according to a perspective published in the March 2018 issue of The American Journal of…

CROI 2018: New approaches to understanding TB can help inform development of better vaccine

With upwards of 2 billion individuals infected with Mycobacterium tuberculosis (Mtb) each year, the infection continues to pose a serious challenge on a global scale. Although advances have been made…

Progress toward a better “shock and kill”?

amfAR-funded scientist Dr. Brad Jones of George Washington University in Washington, DC, has discovered an obstacle to the “shock and kill” strategy for curing HIV that may have implications for…

New way found to defeat HIV latency

SACRAMENTO, Calif., March 7, 2018 — HIV, the virus that causes AIDS, has a secret life. Though anti-retroviral therapy can reduce its numbers, the virus can hide and avoid both…

Novel genome platform reveals new HIV targets

Technology uses digital image analysis to measure protein stability across the human proteome La Jolla, Calif., February 27, 2018 - Sanford Burnham Prebys Medical Discovery Institute (SBP) researchers have developed…

Progress and challenges in TB vaccine development

A publication in F1000Research reviews the progress and challenges in TB vaccine development. "A new TB vaccine is... an inevitability; the question is how long will it take us to…

Queen’s University announces novel drug delivery system with potential to reduce rates of HIV

Queen’s University Belfast is playing a central role in an international consortium that has announced the development of a patch delivery system which will lower the chances of infection for…

Argos announces issuance of patent covering the foundation for manufacturing its HIV immunotherapy

Patent related to strain-independent amplification of HIV nucleic acid sequences DURHAM, N.C., Feb. 15, 2018 -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of…

amfAR renews investment in bioengineering approaches to curing HIV

NEW YORK, Feb. 15, 2018 --- amfAR, The Foundation for AIDS Research, today announced a pair of research grants that renew its support for innovative approaches to HIV cure research.…